SCHEMBL4056702

SCHEMBL4056702

Cc1ccc(-c2nc3ncc(-c4cccc(C(F)(F)F)c4)cc3[nH]2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.44
SCN2A Q99250 2/20 0.43
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 2/20 0.41
TP53 P04637 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
THRB P10828 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054239 0.84 KDM4E (0.52) AURKAKDM4ENPC1ALDH1A1HPGD
SCHEMBL4058461 0.83 SCN2A (0.56) AURKASCN2AKDM4ENPC1ALDH1A1
SCHEMBL13607935 0.83 GRIN1 (0.45) SCN2AKDM4ENPC1ALDH1A1HPGD
SCHEMBL4057030 0.80 SCN2A (0.53) AURKASCN2AKDM4ENPC1ALDH1A1
SCHEMBL4059653 0.79 HTT (0.55) AURKASCN2AKDM4ENPC1ALDH1A1
SCHEMBL4059872 0.78 AURKA (0.61) AURKAGRIN1GRIN2B
SCHEMBL4050873 0.78 AURKA (0.58) AURKASCN2AKDM4ENPC1ALDH1A1
SCHEMBL4051797 0.78 AURKA (0.44) AURKASCN2AKDM4ENPC1ALDH1A1
SCHEMBL4053263 0.77 PDE5A (0.52) AURKASCN2AGRIN1GRIN2B
SCHEMBL4052519 0.76 SCD (0.53) AURKAKDM4ENPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885SCN2A 2825/4885KDM4E 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.